Lynx1 Capital Management Increases Stake in Stoke Therapeutics to 8.1%

On May 18, 2026, Lynx1 Capital Management LP and Weston Nichols filed a Schedule 13G/A regarding their holdings in Stoke Therapeutics, Inc. (STOK). The filing reports that as of March 31, 2026, the reporting persons beneficially own 4,763,673 shares of Common Stock, representing 8.1% of the company based on 59,150,790 shares outstanding. This position includes 4,121,244 shares previously reported for the same quarterly period plus an additional 642,429 shares. Lynx1 Capital Management LP serves as the investment manager for Lynx1 Master Fund LP and a managed account, while Mr. Nichols is the sole member of the general partner of the investment manager. The reporting persons share voting and dispositive power over all reported shares. The filing indicates that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing control of the issuer. This amendment updates the total ownership following the previous quarterly reporting.